Literature DB >> 24524923

The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.

Dimitrios Karussis1.   

Abstract

Multiple sclerosis (MS), is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage. MS is one of the most common causes of neurological disability in young adults. Several variants of MS (and CNS demyelinating syndromes in general) have been nowadays defined in an effort to increase the diagnostic accuracy, to identify the unique immunopathogenic profile and to tailor treatment in each individual patient. These include the initial events of demyelination defined as clinically or radiologically isolated syndromes (CIS and RIS respectively), acute disseminated encephalomyelitis (ADEM) and its variants (acute hemorrhagic leukoencephalitis-AHL, Marburg variant, and Balo's concentric sclerosis), Schilder's sclerosis, transverse myelitis, neuromyelitis optica (NMO and NMO spectrum of diseases), recurrent isolated optic neuritis and tumefactive demyelination. The differentiation between them is not only a terminological matter but has important implications on their management. For instance, certain patients with MS and prominent immunopathogenetic involvement of B cells and autoantibodies, or with the neuromyelitic variants of demyelination, may not only not respond well but even deteriorate under some of the first-line treatments for MS. The unique clinical and neuroradiological features, along with the immunological biomarkers help to distinguish these cases from classical MS. The use of such immunological and imaging biomarkers, will not only improve the accuracy of diagnosis but also contribute to the identification of the patients with CIS or RIS who, are at greater risk for disability progression (worse prognosis) or, on the contrary, will have a more benign course. This review summarizes in a critical way, the diagnostic criteria (historical and updated) and the definitions/characteristics of MS of the various variants/subtypes of CNS demyelinating syndromes.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Clinically isolated syndrome (CIS); Diagnostic criteria; Multiple sclerosis (MS); Neuromyelitis optica (NMO); Radiologically isolated syndrome (RIS)

Mesh:

Substances:

Year:  2014        PMID: 24524923     DOI: 10.1016/j.jaut.2014.01.022

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  72 in total

1.  The relationship of multiple sclerosis and cerebral developmental venous anomaly with an advantageous role in the multiple sclerosis diagnosis.

Authors:  Mohammad Reza Sasani; Ali Reza Dehghan; Nikseresht Ali Reza
Journal:  Iran J Neurol       Date:  2017-10-07

2.  MiR-30a Positively Regulates the Inflammatory Response of Microglia in Experimental Autoimmune Encephalomyelitis.

Authors:  Xue Fang; Dingya Sun; Zhihong Wang; Zhongwang Yu; Weili Liu; Yingyan Pu; Dan Wang; Aijun Huang; Mingdong Liu; Zhenghua Xiang; Cheng He; Li Cao
Journal:  Neurosci Bull       Date:  2017-07-17       Impact factor: 5.203

Review 3.  Endoplasmic reticulum stress and the unfolded protein response in disorders of myelinating glia.

Authors:  Benjamin L L Clayton; Brian Popko
Journal:  Brain Res       Date:  2016-04-04       Impact factor: 3.252

4.  PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Authors:  L Mestre; M Redondo; F J Carrillo-Salinas; J A Morales-García; S Alonso-Gil; A Pérez-Castillo; C Gil; A Martínez; C Guaza
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

Review 5.  Environmental Basis of Autoimmunity.

Authors:  Annarosa Floreani; Patrick S C Leung; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

6.  Subjective and physiological stress measurement in a multiple sclerosis sample and the relation with executive functions performance.

Authors:  Morgana Scheffer; Jefferson Becker; Lucas Araújo de Azeredo; Rodrigo Grassi-Oliveira; Rosa Maria Martins de Almeida
Journal:  J Neural Transm (Vienna)       Date:  2019-02-06       Impact factor: 3.575

Review 7.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 8.  Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.

Authors:  Insha Zahoor; Shailendra Giri
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

9.  Cholinergic imbalance in lumbar spinal cord of a rat model of multiple sclerosis.

Authors:  Chunling Liu; Hui Liu; Hongjun Jin; Xuyi Yue; Zonghua Luo; Zhude Tu
Journal:  J Neuroimmunol       Date:  2018-02-12       Impact factor: 3.478

10.  Emergency Department MRI Scanning of Patients with Multiple Sclerosis: Worthwhile or Wasteful?

Authors:  J Pakpoor; D Saylor; I Izbudak; L Liu; E M Mowry; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2016-10-06       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.